Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:GRCE NASDAQ:MCRB NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.25-3.6%$2.85$1.20▼$6.23$191.87M2.93753,983 shs1.11 million shsGRCEGrace Therapeutics$3.15-2.2%$3.15$1.75▼$4.97$44.53M1.0694,074 shs89,550 shsMCRBSeres Therapeutics$15.91-9.4%$15.82$6.53▼$24.67$153.82M0.15206,039 shs807,240 shsNVCTNuvectis Pharma$6.16-5.4%$7.01$4.44▼$11.80$165.72M-0.2762,679 shs76,495 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-3.56%+10.54%+17.33%+40.69%-46.94%GRCEGrace Therapeutics-2.17%-1.56%-3.96%+10.92%+314,999,900.00%MCRBSeres Therapeutics-9.45%-17.82%-0.38%+112.13%-24.24%NVCTNuvectis Pharma-5.38%-7.78%-3.30%-26.75%-4.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.25-3.6%$2.85$1.20▼$6.23$191.87M2.93753,983 shs1.11 million shsGRCEGrace Therapeutics$3.15-2.2%$3.15$1.75▼$4.97$44.53M1.0694,074 shs89,550 shsMCRBSeres Therapeutics$15.91-9.4%$15.82$6.53▼$24.67$153.82M0.15206,039 shs807,240 shsNVCTNuvectis Pharma$6.16-5.4%$7.01$4.44▼$11.80$165.72M-0.2762,679 shs76,495 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-3.56%+10.54%+17.33%+40.69%-46.94%GRCEGrace Therapeutics-2.17%-1.56%-3.96%+10.92%+314,999,900.00%MCRBSeres Therapeutics-9.45%-17.82%-0.38%+112.13%-24.24%NVCTNuvectis Pharma-5.38%-7.78%-3.30%-26.75%-4.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.14Buy$11.67258.97% UpsideGRCEGrace Therapeutics 3.00Buy$12.00280.95% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67363.02% UpsideNVCTNuvectis Pharma 3.00Buy$15.33148.92% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, BDTX, MCRB, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.008/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/4/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $10.007/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$11.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M2.64N/AN/A$1.47 per share2.21GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AMCRBSeres Therapeutics$126.32M1.10N/AN/A$1.61 per share9.88NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2314.13N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.86N/AN/AN/AN/A-20.36%-18.09%11/12/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)Latest GRCE, BDTX, MCRB, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2026GRCEGrace Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/A8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/A6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73GRCEGrace TherapeuticsN/A8.878.87MCRBSeres TherapeuticsN/A1.571.57NVCTNuvectis PharmaN/A2.662.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%GRCEGrace Therapeutics6.08%MCRBSeres Therapeutics59.34%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%GRCEGrace Therapeutics11.10%MCRBSeres Therapeutics4.70%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableGRCEGrace TherapeuticsN/A13.83 million12.29 millionN/AMCRBSeres Therapeutics3308.75 million8.34 millionOptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableGRCE, BDTX, MCRB, and NVCT HeadlinesRecent News About These CompaniesNuvectis Pharma, Inc. to Participate in H.C. Wainwright Global Investment Conference with On-Demand Presentation and Virtual MeetingsSeptember 4, 2025 | quiverquant.comQNuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comNuvectis Pharma, Inc.August 26, 2025 | cnn.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateAugust 18, 2025 | marketbeat.comQ3 EPS Estimates for Nuvectis Pharma Lifted by HC WainwrightAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Nuvectis Pharma Boosted by Roth CapitalAugust 16, 2025 | marketbeat.comNuvectis Pharma FY2028 EPS Forecast Raised by Roth CapitalAugust 15, 2025 | marketbeat.comNuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 12, 2025 | finanznachrichten.deNuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 11, 2025 | globenewswire.comNuvectis (NVCT) Q2 Loss Widens 43%August 5, 2025 | fool.comNuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 5, 2025 | globenewswire.comNuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation StudyJuly 31, 2025 | globenewswire.comNuvectis Pharma Insiders Added US$2.50m Of Stock To Their HoldingsJuly 29, 2025 | finance.yahoo.comNuvectis Pharma Inc News (NVCT) - Investing.comJuly 18, 2025 | investing.comNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading TherapiesJuly 8, 2025 | finance.yahoo.comMarlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 25, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of StockJune 21, 2025 | insidertrades.comInsiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchasesJune 18, 2025 | finance.yahoo.comNuvectis Pharma: Still Interesting, But Still Too Risky To Jump InJune 18, 2025 | seekingalpha.comNuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2025 | globenewswire.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 SharesMay 14, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, BDTX, MCRB, and NVCT Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$3.25 -0.12 (-3.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.27 +0.02 (+0.62%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Grace Therapeutics NASDAQ:GRCE$3.15 -0.07 (-2.17%) As of 09/12/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Seres Therapeutics NASDAQ:MCRB$15.91 -1.66 (-9.45%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.44 -0.47 (-2.92%) As of 09/12/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Nuvectis Pharma NASDAQ:NVCT$6.16 -0.35 (-5.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.36 +0.20 (+3.23%) As of 09/12/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
